141 related articles for article (PubMed ID: 22207214)
1. Production of bioactive, SUMO-modified, and native-like TNF-α of the rhesus monkey, Macaca mulatta, in Escherichia coli.
Jia D; Yang H; Wan L; Cheng J; Lu X
Appl Microbiol Biotechnol; 2012 Mar; 93(6):2345-55. PubMed ID: 22207214
[TBL] [Abstract][Full Text] [Related]
2. Recombinant production of bioactive human TNF-alpha by SUMO-fusion system--high yields from shake-flask culture.
Hoffmann A; Müller MQ; Gloser M; Sinz A; Rudolph R; Pfeifer S
Protein Expr Purif; 2010 Aug; 72(2):238-43. PubMed ID: 20363332
[TBL] [Abstract][Full Text] [Related]
3. Human SUMO fusion systems enhance protein expression and solubility.
Wang Z; Li H; Guan W; Ling H; Wang Z; Mu T; Shuler FD; Fang X
Protein Expr Purif; 2010 Oct; 73(2):203-8. PubMed ID: 20457256
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells.
Scherf U; Benhar I; Webber KO; Pastan I; Brinkmann U
Clin Cancer Res; 1996 Sep; 2(9):1523-31. PubMed ID: 9816329
[TBL] [Abstract][Full Text] [Related]
5. Expression and purification of an antitumor-analgesic peptide from the venom of Mesobuthus martensii Karsch by small ubiquitin-related modifier fusion in Escherichia coli.
Cao P; Yu J; Lu W; Cai X; Wang Z; Gu Z; Zhang J; Ye T; Wang M
Biotechnol Prog; 2010; 26(5):1240-4. PubMed ID: 20945481
[TBL] [Abstract][Full Text] [Related]
6. SUMO fusion facilitates expression and purification of garlic leaf lectin but modifies some of its properties.
Upadhyay SK; Saurabh S; Rai P; Singh R; Chandrashekar K; Verma PC; Singh PK; Tuli R
J Biotechnol; 2010 Mar; 146(1-2):1-8. PubMed ID: 20100526
[TBL] [Abstract][Full Text] [Related]
7. Expression and purification of soluble human APRIL in Escherichia coli using ELP-SUMO tag.
Zhang J; Ma L; Zhang SQ
Protein Expr Purif; 2014 Mar; 95():177-81. PubMed ID: 24412409
[TBL] [Abstract][Full Text] [Related]
8. SUMO fusion technology for enhanced protein production in prokaryotic and eukaryotic expression systems.
Panavas T; Sanders C; Butt TR
Methods Mol Biol; 2009; 497():303-17. PubMed ID: 19107426
[TBL] [Abstract][Full Text] [Related]
9. Strategies for the expression of SUMO-modified target proteins in Escherichia coli.
Saitoh H; Uwada J; Azusa K
Methods Mol Biol; 2009; 497():211-21. PubMed ID: 19107420
[TBL] [Abstract][Full Text] [Related]
10. Improved expression of a soluble single chain antibody fusion protein containing tumor necrosis factor in Escherichia coli.
Kim S; Cheung LH; Zhang W; Rosenblum MG
Appl Microbiol Biotechnol; 2007 Nov; 77(1):99-106. PubMed ID: 17703297
[TBL] [Abstract][Full Text] [Related]
11. Minimal tumor necrosis factor receptor binding protein: optimum biological activity of a truncated p55 soluble tumor necrosis factor receptor-IgG fusion protein.
Corcoran AE; Scallon BJ; Trinh H; Chernajovsky Y; Ghrayeb J; Feldmann M
Eur Cytokine Netw; 1998 Sep; 9(3):255-62. PubMed ID: 9831174
[TBL] [Abstract][Full Text] [Related]
12. Soluble expression, rapid purification, and characterization of human interleukin-24 (IL-24) using a MBP-SUMO dual fusion system in Escherichia coli.
Zhang J; Lv X; Xu R; Tao X; Dong Y; Sun A; Wei D
Appl Microbiol Biotechnol; 2015 Aug; 99(16):6705-13. PubMed ID: 25681151
[TBL] [Abstract][Full Text] [Related]
13. Production of a cytotoxic cationic antibacterial peptide in Escherichia coli using SUMO fusion partner.
Li JF; Zhang J; Song R; Zhang JX; Shen Y; Zhang SQ
Appl Microbiol Biotechnol; 2009 Aug; 84(2):383-8. PubMed ID: 19582446
[TBL] [Abstract][Full Text] [Related]
14. Production of recombinant peptides as fusions with SUMO.
Satakarni M; Curtis R
Protein Expr Purif; 2011 Aug; 78(2):113-9. PubMed ID: 21586326
[TBL] [Abstract][Full Text] [Related]
15. SUMO fusion technology for enhanced protein expression and purification in prokaryotes and eukaryotes.
Peroutka Iii RJ; Orcutt SJ; Strickler JE; Butt TR
Methods Mol Biol; 2011; 705():15-30. PubMed ID: 21125378
[TBL] [Abstract][Full Text] [Related]
16. Construction and expression of sTRAIL-melittin combining enhanced anticancer activity with antibacterial activity in Escherichia coli.
Liu H; Han Y; Fu H; Liu M; Wu J; Chen X; Zhang S; Chen Y
Appl Microbiol Biotechnol; 2013 Apr; 97(7):2877-84. PubMed ID: 23149754
[TBL] [Abstract][Full Text] [Related]
17. Enrichment of fermentation media and optimization of expression conditions for the production of EAK(16) peptide as fusions with SUMO.
Satakarni M; Koutinas AA; Webb C; Curtis R
Biotechnol Bioeng; 2009 Feb; 102(3):725-35. PubMed ID: 18973282
[TBL] [Abstract][Full Text] [Related]
18. A novel human tumor necrosis factor alpha mutant showed potent antitumor activity and reduced toxicity in vivo.
Lu F; Chen ZM; Liu QH; Chen CQ
Acta Pharmacol Sin; 2001 Jul; 22(7):619-23. PubMed ID: 11749826
[TBL] [Abstract][Full Text] [Related]
19. Soluble expression and purification of the recombinant bioactive peptide precursor BPP-1 in Escherichia coli using a cELP-SUMO dual fusion system.
Rao S; Zang X; Yang Z; Gao L; Yin Y; Fang W
Protein Expr Purif; 2016 Feb; 118():113-9. PubMed ID: 26581779
[TBL] [Abstract][Full Text] [Related]
20. High level soluble production of functional ribonuclease inhibitor in Escherichia coli by fusing it to soluble partners.
Guo W; Cao L; Jia Z; Wu G; Li T; Lu F; Lu Z
Protein Expr Purif; 2011 Jun; 77(2):185-92. PubMed ID: 21292012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
